MORAb-066

N/A

Report date: 2024/06/27 20:00:09

Base Information

Drug NameMORAb-066
Drug Alias NameMORAb-066
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTissue factor inhibitors
TargetsTissue factor
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMorphotek Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsColorectal Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A